The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
- Read more about RYBREVANT got FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/rybrevant-got-fda-approval-as-the-first-targeted-treatment-for-patients-with-non-small-cell-lung-cancer
No comments:
Post a Comment